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Abstract: Introduction: Despite the fact that the elderly constitute an increasingly important group of patients with acute 
coronary syndrome (ACS), they are often excluded from clinical trials and are underrepresented in clinical registries.  
Aims: To evaluate the impact of age in patients hospitalized with ACS.  
Methods: Data collected for all patients presenting with ACS (n=16,744) who were admitted in Qatar during the period 
(1991-2010) and were analyzed according to age into 3 groups (≤50 years [41.4%], 51-70 years [48.7%] and >70 years 
[9.8%]). 
Results: Older patients were more likely to be women and have hypertension, diabetes mellitus, and renal failure, while 
younger patients were more likely to be smokers. Non-ST-elevation myocardial infarction and heart failure were more 
prevalent in older patients. Older age was associated with undertreatment with evidence-based therapies and had higher 
mortality rate. Age was independent predictor for mortality. Over the study period, the relative reduction in mortality rates 
was higher in the younger compared with the older patients (61, 45.9 and 35.5%). 
Conclusions: Despite being a higher-risk group, older patients were undertreated with evidence based therapy and had 
worse short-term outcome. Guidelines adherence and improvement in hospital care for elderly patients with ACS may 
potentially reduce morbidity and mortality. 
Keywords:  Age,  acute  coronary  syndrome,  ST-elevation  myocardial  infarction,  non-ST-elevation  myocardial  infarction, 
unstable angina, death. 
INTRODUCTION 
  Age is the most important determinant of acute coronary 
syndrome (ACS) outcomes [1]. Approximately 33% of  all 
ACS  episodes  occur  in  patients  over  75  years  and  they 
account  for  about  60%  of  the  overall  mortality  [2].  The 
Global  Registry  of  Acute  Coronary  Events  (GRACE) 
reported 89.9% of the in-hospital prognostic outcome can be 
attributed  to  8  parameters;  one  of  which  is  age  [3].  The 
burden of coronary artery disease (CAD) will increase in the 
next  few  years  with  an  ageing  population.  Furthermore, 
cardiovascular medication side effects are more common in 
elderly  patients  due  to  differences  in  drug  absorption, 
metabolism, distribution and excretion. Therefore, selecting 
treatment  to  avoid  adverse  drug  interactions  as  well  as 
ensuring  appropriate  dose  adjustment  in  older  patients  is 
crucial [1]. Moreover, adverse events are more common in 
the elderly. The complication rates of percutaneous coronary  
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interventions  (PCI),  thrombolysis,  anticoagulation  and 
antiplatelet  therapies  exceed  that  observed  in  younger 
patients  [1].  Unfortunately,  elderly  patients,  who  are  at  a 
high risk of morbidity and mortality from ACS, are being 
treated suboptimally (treatment-risk paradox) [4,5].  
  In the present study we evaluate the impact of age on the 
clinical presentation, management and in-hospital outcomes 
in  a  large  sample  of  patients  hospitalized  with  ACS  in  a 
Middle-eastern country over a 20-year period. 
MATERIALS AND METHODS 
Study Setting 
  Qatar  has  a  population  of  about  1.6  million  (2010 
census), consisting of Qatari and other Middle-Eastern Arabs 
(<40%)  and  non-Middle-Eastern  individuals.  The  vast 
majority  of  the  latter  population  is  mainly  from  India, 
Pakistan, Nepal and Bangladesh.  
  The present study was based at Hamad General Hospital, 
Doha, Qatar. This hospital provides inpatient and outpatient 
tertiary  care  in  medicine  and  surgery  for  the  residents  of 
Qatar;  nationals  and  expatriates  where  more  than  95%  of Age and Acute Coronary Syndrome  The Open Cardiovascular Medicine Journal, 2012, Volume 6    61 
cardiac patients are treated in the country making it an ideal 
center  for  population-based  studies.  The  vast  majority  of 
ACS and heart failure (HF) patients (>95%) are admitted to 
this  hospital.  In  the  last  decade  of  the  20
th  century, 
cardiovascular diseases were the leading causes of morbidity 
and mortality in the country [6]. 
  The  Cardiology  and  Cardiovascular  Surgery  Database 
maintained  electronically at Hamad General Hospital from 
January 1991 to December, 2010 was used for this study. 
Cardiology  Inpatient  Data  forms  were  completed  by 
physicians at the time of patient discharge from the hospital 
according  to  predefined  criteria.  These  records  have  been 
coded  and  registered  at  the  cardiology  department  since 
January 1991 [7,8]. Data registered into a computer by a data 
entry operator were randomly checked by physicians at the 
cardiology department. 
  Patients  were  divided  into  3  groups  according  to  their 
age:  ≤50,  51-70  and  >70  years.  Ethical  clearance  was 
obtained from the MRC Research Committee, HMC. 
DEFINITIONS 
  Diagnosis of the different types of ACS and definitions 
of  data  variables  were  based  on  the  American  College  of 
Cardiology (ACC) clinical data standards [9]. Use of adjunct 
therapy  during  hospitalization  was  recorded  for  every 
patient.  The  presence  of  diabetes  mellitus  (DM)  was 
determined by the documentation in the patient’s previous or 
current  medical  record  of  a  documented  diagnosis  of  DM 
that  had  been  treated  with  medication  or  insulin.  The 
presence  of  dyslipidemia  was  determined  by  the 
demonstration of a fasting cholesterol > 5.2 mmol/L in the 
patient’s  medical  record,  or  any  history  of  treatment  of 
dyslipidemia  by  the  patient’s  physician.  Chronic  renal 
impairment  was  defined  as  creatinine  >1.5  upper  normal 
range  (124  µmol/L).  The  presence  of  hypertension  (HTN) 
was determined by any documentation in the medical record 
of HTN or if the patient was on treatment. Smoking history: 
patients  were  divided  into  current  cigarette  smokers,  past 
smokers  (defined  as  more  than  6  months  abstinence  from 
smoking) and those who never smoked [7]. 
STATISTICAL ANALYSIS 
  Data  were  presented  in  the  form  of  frequency  and 
percentages  for  categorical  variables  and  mean  ±  standard 
deviation (SD) for interval variables. Baseline demographic 
characteristics,  past  medical  history,  clinical  presentation, 
medical  therapy,  cardiac  procedures  and  clinical  outcomes 
were compared between the 3 age groups (≤50, 51-70 and 
>70 years). Statistical  analyses were conducted using One 
Way ANOVA for interval variables and Pearson chi-square 
(χ
2) tests for categorical variables. Variables influencing in-
hospital  mortality  was  assessed  with  multiple  logistic 
regressions enter method. Adjusted Odds Ratios (OR), 95% 
CI, and p values were reported for significant predictors. All 
p  values  were  2-tailed  and  values  <0.05  were  considered 
significant.  Statistical  Package  for  Social  Sciences  (SPSS) 
version 19.0 was used for the analysis. 
RESULTS 
  Between  the  years  1991  to  end  of  2010,  16,744  of 
patients were admitted with ACS. 6946 (41.5%) patients of 
them were aged ≤50 years, 8158 (48.7%) were between 51 
and  70  years  and  1640  (9.8%)  patients  were  >70  years 
old.7200  (43%)  patients  presented  with  ST-elevation 
myocardial infarction (MI), 5577 (33%) patients with Non-
ST  elevation  MI  and  3967  (24%)  patients  with  unstable 
angina (UA). 
CLINICAL  PRESENTATION  AND  BASELINE 
PATIENT CHARACTERISTICS (TABLE 1) 
  The  mean  age  of  patients  was  54  ±  11.9  years  (6946 
patients were aged ≤50 years, 8158 were between >50 and 
70  years  and  1640  patients  were  >70  years  old).  Women 
were  increasingly  represented  with  increasing  age.  HTN, 
DM , renal failure, prior MI and prior coronary artery bypass 
graft  (CABG)  were  more  prevalent  among  older  patients, 
while the prevalence of current smoking, family history of 
CAD and prior PCI were highest in the younger age group (P 
= 0.001). There was no significant difference among the 3 
age groups with respect to dyslipidemia. Older patients were 
more likely to present with non-typical ischemic symptoms 
including higher frequency of palpitations and dyspnea when 
compared with the younger age groups. Older patients were 
more  likely  to  present  with  non-ST-  elevation  MI,  while 
younger  patients  were  more  likely  to  present  with  ST-
elevation MI (P = 0.001). 
  A  higher  level  of  mean  total  cholesterol,  serum 
triglyceride and low-density lipoprotein were more prevalent 
in patients aged ≤ 70 years. Left ventricular ejection fraction 
(LVEF)  <40%  was  more  prevalent  in  the  elderly  than  in 
patients ≤50 years (34 vs 27%, P = 0.001). 
MANAGEMENT (TABLE 2) 
  On  admission,  the  elderly  were  less  likely  to  receive 
evidence-based therapies. The use of aspirin and β-blockers 
were more prevalent in the younger age group (P = 0.001). 
Clopidogrel  use  was  higher  among  the  middle-age  group 
when  compared  with  the  other  2  groups.  Elderly  patients 
with ST-elevation MI were less likely to receive thrombolytic 
therapy when compared with the younger age groups. Also, 
with elderly with ACS were less likely than patients ≤ 50 
years  to  undergo  coronary  angiography  (4  vs  17%),  to 
receive  glycoprotein  (GP)  IIb/IIIa  inhibitors,  and  to  be 
treated  by  PCI  (5  vs  12%).  However,  CABG  surgery 
performance within the same hospitalization increased from 
2% among patients ≤50 years to 7% in patients >70 years (P 
= 0.001 for all). The use of β-blockers was more frequent in 
men  compared  with  women  in  age  ≤50  (55  vs  48%)  and 
between 51 and 70 years (49 vs 41%), (P = 0.001 for each). 
The use of angiotensin-converting enzyme (ACE) inhibitors 
(33 vs 25%) was higher in men compared with women in age 
≤50 years. However, there was no significant difference in 
the use of β-blockers and ACE inhibitors in both genders in 
the other age groups. 
  The  use  of  unfractionated  heparin  was  more  prevalent 
among  patients  ≤  50  years,  whereas,  the  low  molecular 
weight (LMW) heparin was more prevalent among patients 
>50  years  (p  =  0.001).  Also,  ACE  inhibitors/angiotensin-
receptor  blockers  (ARBs)  use  was  highest  among  patients 
>50 years old (p = 0.001). 62    The Open Cardiovascular Medicine Journal, 2012, Volume 6  Ahmed et al. 
On Discharge 
  Elderly patients were less likely than patients aged ≤50 
years to be treated with aspirin (76 vs 93%) and β-blockers 
(25 vs 34%). On the other hand, patients in the age group  
51-70 years were more likely  than other age groups to be 
treated  with  clopidogrel,  ACE  inhibitors/ARBs  and  statins  
(p = 0.001).  
OUTCOME (TABLE 3) 
  Mortality  rates  across  20-year  period  in  different  age 
groups are shown in Fig. (2B). Older age ACS patients had 
significantly  higher  in-hospital  mortality  rate,  cardiogenic 
shock, cardiac arrest, heart failure and stroke when compared 
with the younger age groups (p = 0.001). The mortality rates 
were higher in women when compared with men in all age 
groups  [7.3  vs  3.1%  in  age  ≤50  (P=0.001),  9%  vs  5.4% 
(P=0.001) in between 51-70, and 17.2 vs 13% in age > 70 
years (P=0.03).  
TREND  OF  HOSPITALIZATION  AND  OUTCOME 
(TABLE 4, FIGS. 1 AND 2) 
  Over  the  20-year  period,  there  was  an  increase  in  the  
total  number  of  patients  hospitalized  with  ACS  and  was 
Table 1.  ACS Patient Characteristics and Co-morbidities According to Age 
Variables  Age≤50 
Years 
Age 51-70 
Years  
Age >70  
Years 
P  
Number (%)  6946(41.5)  8158(48.7)  1640(9.8)   
Sex (female)  410(5.9)  1510(18.5)  553(33.7)  0.001 
Cardiovascular risk factors (%) 
•  Hypertension  1871(26.9)  4011(49.2)  1015(61.9)  0.001 
•  Diabetes mellitus  1984(28.6)  4095(50.2)  882(53.8)  0.001 
•  Dyslipidemia  1510(21.7)  1726(21.2)  320(19.5)  0.14 
•  Current smoker  3104(44.7)  2309(28.3)  176(10.7)  0.001 
•  Chronic Renal impairment  68(1)  334(4.1)  159(9.7)  0.001 
•  Family history of CAD  222(3.2)  154(1.9)  21(1.3)  0.001 
Prior cardiovascular disease (%) 
•  Prior MI  781(11.2)  1579(19.4)  429(26.2)  0.001 
•  Prior PCI  800(11.5)  859(10.5)  82(5)  0.001 
•  Prior CABG  124(1.8)  449(5.5)  120(7.3)  0.001 
Total cholesterol (mmol/L)  5.2±1.3  4.9±1.2  4.5±1.2  0.001 
Serum triglyceride (mmol/L)  2.2±1.3  1.9±1.1  1.5±0.8  0.001 
Low density lipoprotein (mmol/L)  3.1±1.1  2.8±1.1  2.5±0.9  0.001 
High density lipoprotein (mmol/L)  0.97±0.3  1.02±0.3  1.1±0.4  0.001 
Troponin T (ng/ml)  40.6  44  43.6   
CK-MB (u/L)  270±795  204±710  143±675   
Atypical chest pain (%)  864(12.4)  1010(12.4)  163(9.9)  0.02 
Ischemic chest pain (%)  5397(77.7)  6079(74.5)  1042(63.5)  0.001 
Palpitations (%)  114(1.6)  186(2.3)  60(3.7)  0.001 
Dizziness (%)  137(2)  189(2.3)  33(2.0)  0.32 
Shortness of breath (%)  434(6.2)  1286(15.8)  467(28.5)  0.001 
ST-elevation MI (%)  3695(53.2)  3098(38)  407(24.8)   
NST- elevation MI (%)  1872(27)  2918(35.8)  787(48)   
Unstable angina (%)  1379(19.9)  2142(26.3)  446(27.2)  0.001 
Abbreviations: CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery; NST-elevation, non ST 
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Table 2.  In-hospital Management and Discharge Medication According to Age 
Variables 
Number (%) 
Age ≤50 
Years  
Age 51-70  
Years 
Age > 70 
Years 
P  
1
st 24 h therapy  
•  Aspirin  6424(92.5)  7365(90.3)  1379(84.1)  0.001 
•  Clopidogrel  2126(30.6)  2897(35.5)  542(33)  0.001 
•  Beta blockers  3786(54.5)  3887(47.6)  594(36.2)  0.001 
•  ACE inhibitors/ARBs  1801(25.9)  2797(34.3)  572(34.9)  0.001 
•  Thrombolysis therapy  2690(38.7)  1945(23.8)  119(7.3)  0.001 
•  GP IIb/IIIa inhibitors  309(4.4)  392(4.8)  45(2.7)  0.001 
•  Unfractionated Heparin  3044(43.8)  2870(35.2)  497(30.3)  0.001 
•  LMWH  1192(17.2)  1643(20.1)  335(20.4)  0.001 
Coronary angiography  1145(16.5)  824(10.1)  60(3.7)  0.001 
PCI  800(11.5)  859(10.5)  82(5)  0.001 
CABG  124(1.8)  449(5.5)  120(7.3)  0.001 
LVEF <40%  439(26.5)  827(35.6)  242(33.8)  0.001 
Discharge medications  
•  Aspirin  6445(92.8)  7223(88.5)  1246(76)  0.001 
•  Clopidogrel  2233(32.1)  2987(36.6)  541(33)  0.001 
•  Beta-Blockers  2341(33.7)  2389(29.3)  402(24.5)  0.001 
•  ACE inhibitors/ARBs  2560(36.9)  3516(43.1)  645(39.3)  0.001 
•  Statins  3422(49.3)  4460(54.7)  791(48.2)  0.001 
Abbreviations: ACE inhibitors,angiotensin-converting enzyme inhibitors;ARBs,angiotensin-receptor blockers; GP IIb/IIIa inhibitors, glycoprotein IIb/IIIa inhibitors; LMWH, low 
molecular weight heparin; LVEF, Left ventricular ejection fraction.  
 
Table 3.  In-hospital Outcomes According to Age 
Variables  
Number (%)  
Age ≤50 
Years 
Age 51-70  
Years 
Age >70 
Years 
P 
Heart failure  137(2)  394(4.8)  154(9.4)  0.001 
Shock  133(1.9)  247(3.0)  83(5.1)  0.001 
Cardiac arrest  236(3.4)  421(5.2)  182(11.1)  0.001 
Stroke  14(0.2)  31(0.4)  12(0.7)  0.003 
Death  231(3.3)  494(6.1)  237(14.5)  0.001 
 
Table 4.  Trends in the Number of Admissions and In-hospital Mortality Rates Over the 20-years Study Period  
Years  1991-94  1995-98  1999-02  2003-06  2007-10   P 
Number (%)  1775(10.6)  1836(11)  2412(14.4)  4655(27.8)  6072(36.3)   
Age (Mean ±SD, years)  51.7±12  51.7±11.6  54.4±12  54.9±11.7  54.5±11.7  0.001 
Death (%)  175(9.9)  168(9.2)  213(8.8)  212(4.6)  195(3.2)  0.001 
Age ≤50 years  45 (5.2)  43 (4.7)  57 (5.5)  48 (2.8)  36 (1.5)  0.001 
Age 51-70 years  81 (11.1)  95 (12)  109 (9.8)  106 (4.4)  103 (3.3)  0.001 
Age >70 years  47 (33.8)  30 (25.2)  47 (17.5)  57 (11.8)  56 (8.9)  0.001 64    The Open Cardiovascular Medicine Journal, 2012, Volume 6  Ahmed et al. 
 
Fig. (1). Trends in the number of hospitalization of patients according to age. 
Fig. (2). Trends in in-hospital mortality rates over the study period. 
accompanied by higher percentage of older age patients. The 
overall,  in-hospital  mortality  rates  significantly  decreased 
from 9.9 to 3.2%, this decrease in mortality rates occurred 
regardless of age (Fig. 2A). When the mortality rates for the 
period 1991 to 2006 were combined and compared with the 
period of 2007 to 2010, the relative reduction in mortality 
rates was higher in the younger patients when compared with 
the older patients (61, 45.9 and 35.5%).  Age and Acute Coronary Syndrome  The Open Cardiovascular Medicine Journal, 2012, Volume 6    65 
MULTIPLE  LOGISTIC  REGRESSION  ANALYSIS 
(TABLE 5) 
  Advancing age (OR 1.47; 95% CI 1.24-1.74 for age 51-
70  and  OR  3.09;  95%CI  2.51-3.82,  for  age  >  70  years), 
female gender, DM, chronic renal impairment, heart failure 
and prior history of MI were independent predictors of death.  
DISCUSSION 
  We  showed  increased  in-hospital  mortality  in  older 
compared with younger ACS patients. Despite the fact that 
older ACS patients were a higher risk group when compared 
with younger patients, they were undertreated with evidence-
based therapies. Older age was independent predictor of in-
hospital  mortality.  Furthermore,  this  decrease  in  mortality 
rates was more substantial in the younger age groups. This 
improvement in outcome may be attributed, at least in part, 
to increased use of evidence-based therapies. 
THE  PREVALENCE  AND  CLINICAL  CHARAC- 
TERISTICS OF OLDER AGE PATIENTS  
  The mean age of the population (54 years) in the present 
study  (1991-2010)  is  comparable  to  that  reported  in  the 
Indian  CREATE  registry  (2005)  [10]  and  Gulf  RACE 
(Registry of Acute  Coronary Events)  Registry (6-  Middle-
eastern countries, 2007) [11] and was significantly younger 
when compared with reports from the 1
st and 2
nd Euro Heart 
Surveys (2002 and 2006) [12,13] and GRACE (2003) [3]. 
Consistent  with  a  previous  study  [14],  the  proportion  of 
women increased with increasing age.  
  The percentage of elderly patients ≥70 years was 21% in 
the  ACCESS  (ACute  Coronary  Events  -  a  multinational 
Survey of current management Strategies) [15] and 13% in 
the  CREATE  registry  which  were  higher  than  reported  in  
the current study (9.8%). This may be attributed to the fact 
that  similar  to  other  Middle-eastern  Gulf  countries,  the 
population in Qatar is younger when compared with other 
parts of the World, with an overall median age of 30.8 years 
(men;  32.9  years  and  women;  25.5  years),  2011  estimate 
(CIA factbook). Consistent with a previous study [14], the 
clinical  characteristics  of  ACS  patients  vary  according  to 
age.  The  most  prevalent  CAD  risk  factors  in  the  younger 
patients  was  current  smoking,  family  history  of  CAD  
and prior PCI, whereas history of DM, HTN, renal failure, 
prior MI and CABG were more common in elderly patients. 
These  variations  in  risk  factor  patterns  in  young  and  
elderly  patients  highlight  the  urgent  need  for  international 
awareness, real effort and national policies for primary and 
secondary prevention of CAD. 
CLINICAL PRESENTATION AND ACS TYPE 
  Older  ACS  patients  were  less  likely  to  present  with 
typical  chest  pain  than  younger  patients  and  this  atypical 
presentation may increase the risk of misdiagnosis and delay 
diagnosis.  In  terms  of  ACS  types,  as  in  previous  studies 
[14,16],  older  patients  were  more  likely  to  have  Non-ST-
elevation  MI  and  the  proportion  of  ST-elevation  MI 
decreased  with  increasing  age.  In  the  present  study,  the 
frequency of ST-elevation MI constituted two-fifths of our 
patients  compared  with  one-third  in  other  ACS  survey 
[4,14]. This may be attributed to the relatively younger age 
group of ACS (54 years), which is almost a decade younger 
than those reported from developed countries [16].  
HOSPITAL MANAGEMENT AND OUTCOMES  
  Although, CRUSADE (Can Rapid Risk Stratification of 
Unstable Angina Patients Suppress Adverse Outcomes With 
Early Implementation of the ACC/AHA Guidelines) database 
[2,17]  suggested  that  advanced  patient  age  (>90  years) 
should not be a contraindication for early aggressive treat- 
ment  which  was  associated  with  lower  rate  in-hospital 
mortality when compared to patients treated with conservative 
approach,  the  current  study  demonstrated  the  paradox  of 
undertreatment  of  older  patients  when  compared  with  the 
younger age group.  
  Our  data  is  concordant  with  other  studies  [2,16,18,19] 
showing  that  older  patients  were  less  likely  to  receive 
evidence-based ACS medications and coronary angiography 
than their younger counterparts. It should be noted that there 
is no age limitation to the use of fibrinolytic therapy among 
ST-elevation MI patients and prompt reperfusion for patients 
with  ST-elevation  MI  is  a  class  1  ACC/AHA  guideline 
recommendation  and  has  been  shown  to  reduce  mortality 
[20]. In the present study, the highest proportion of patients 
who  received  thrombolytic  therapy  was  the  younger  age 
group. Also, most of elderly patients presenting with ACS 
were treated conservatively during the same admission with 
only  3.7%  offered  coronary  angiography  and  only  5% 
undergoing PCI. The use of GP IIb/IIIa inhibitors was very 
low in all ACS strata, the highest being among the middle-
age group when compared with the other 2 groups.  
  In the GRACE analysis [21], 4 factors were found to be 
strongly  related  to  lack  of  reperfusion  therapy  use  among 
Table 5.  Multivariable Risk factors for In-Hospital Mortality 
Variables  Adjusted OR  95% C.I.  P  
Gender Male  0.64  0.55 – 0.76  0.001 
Smoking  0.67  0.57 – 0.80  0.001 
DM  1.43  1.24 – 1.66  0.001 
HTN  0.62  0.53 – 0.72  0.001 
Dyslipidemia  0.67  0.56 – 0.80  0.001 
Family History of CAD  0.64  0.35 – 1.18  0.15 
Prior MI  1.30  1.10 – 1.53  0.002 
Prior PCI  0.56  0.42 – 0.76  0.001 
Chronic Renal impairment  1.70  1.29 – 2.23  0.001 
Prior CABG  0.60  0.42 – 0.86  0.005 
Heart Failure  2.81  2.36 – 3.33  0.001 
Age 51 – 70 Year  1.47  1.24 – 1.74  0.001 
Age > 70 Year  3.09  2.51 – 3.82  0.001 
Abbreviations: DM, diabetes mellitus; HTN, hypertension.  
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ST-elevation  MI  patients;  age  ≥75  years,  prior  congestive 
HF,  prior  MI  or  prior  CABG  surgery.  Other  variables 
associated  with  not  offering  reperfusion  were  female, 
diabetes, and delayed presentation [21, 22]. 
  In our study, only a small number of patients underwent 
CABG surgery during the same admission which occurred 
mostly  in  the  older  group  (7.3%)  and  this  is  most  likely 
attributed  to  the  fact  they  were  more  likely  to  have  more 
severe and extensive CAD when compared with the younger 
age. In a prior study [16], the rate of CABG surgery was 
highest  among  patients  aged  65-74  years  (8.1%)  when 
compared with the younger and older age groups.  
  Prior data reported the long-term benefit of β-blockade 
use (in elderly patients) and ACE inhibitors use (regardless 
of age) after ACS [23,24]. The current study showed that the 
use of evidence-based medical therapies at hospital discharge 
was less common in the elderly when compared with those  
≤  70 years.  The  use  of  β-blockade  decreased  significantly 
with  increasing  age  and  the  use  of  ACE  inhibitors/ARBs, 
clopidogrel and statins was more prevalent in age group 51-
70 years (P = 0.001). 
  In  previous  studies  [2,14,16],  age  was  found  to  be  an 
independent  predictor  of  worse  in-hospital  outcomes  after 
ACS. In the present study, the short-term outcome in older 
patients  was  poor,  with  increased  risk  of  HF,  cardiogenic 
shock and cardiac arrest. Also, the in-hospital mortality due 
to any type of ACS was increased from 3.3-6.1% in patients 
<70 years of age to 14.5% in patients >70 years of age.  
  Following adjustment for relevant variables the adjusted 
odds ratio for in-hospital mortality was 1.59 for patients age 
51 - 70 years and 3.65 for those age >70 years. The overall 
worse prognosis in elderly is multifactorial due to increasing 
age  itself  [1,14],  high  prevalence  of  cardiovascular  risk 
factors, atypical presentation of ACS, impaired left ventricular 
systolic  function  [25]  and  the  under  use  of  Guideline-
recommended medical and interventional therapies [1, 2, 14].  
TRENDS  
  The  current  study  reported  significant  reduction  in 
mortality  over  the  20-year  period  regardless  of  age;  this 
significant improvement may be attributed to improvement 
in health care in terms of early diagnosis and more use of 
evidence-based therapies. Although the overall use was low, 
further efforts are needed to optimize their use, which may 
improve outcomes further. The mortality rates in women was 
significantly higher than in men regardless of age and this 
increased mortality rates was in part related to the fact that 
women were less likely to be managed with evidence based 
therapies [7,26]. 
LIMITATION OF THE STUDY 
  Our  study  is  constrained  by  the  limitations  inherent  in  
all  studies  of  historical,  observational  design.  Inaccuracies  
in  the  diagnosis  and  coding  of  ACS  in  routine  data  are  
well  recognized  and  we  relied  on  the  accuracy  of  such  
data. Temporal changes in referral and coding practices, in 
diagnostic  accuracy,  and  in  awareness  of  ACS  as  a 
diagnostic  entity  may  have  influenced  our  findings.  Other 
study limitations could include missing data or measurement 
errors, possible confounding by variables not controlled for, 
as  this  was  an  observational  and  single-center  study.  Our 
study  focused  on  in-hospital  outcomes  and  long-term  data 
were  not  available.  There  have  been  some  changes  in 
emphasis in treatment options since the data were recorded. 
Nevertheless, to the best of our knowledge the current study 
addresses unique findings of patients hospitalized with ACS 
conduced in a large population of patients over a longtime 
period. 
CONCLUSIONS 
  The  clinical  characteristics  of  ACS  Middle-eastern 
patients vary considerably with age. Despite being higher-
risk group, older patients were undertreated with evidence 
based therapy and had worse short-term outcome. Guidelines 
adherence  and  improvement  in  hospital  care  for  elderly 
patients  with  ACS  may  potentially  reduce  morbidity  and 
mortality. 
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